Guillaume Breton | Clinical & Statistical Programming Head for Oncology DU
Johnson & Johnson Innovative Medicine
Guillaume Breton is the Head of Clinical & Statistical Programming for Oncology at Johnson & Johnson, where he leads global teams supporting late stage development and regulatory submissions across a broad oncology portfolio. He joined J&J in 2024 and brings more than 25 years of experience in the pharmaceutical industry, spanning CRO and large biopharma environments. Before joining Johnson & Johnson, Guillaume spent many years at Novartis in Basel, where he held senior leadership roles and built high performing statistical programming organizations supporting global clinical development. His expertise includes oncology development, regulatory submissions, vendor and FSP oversight, and large scale operational transformation. Guillaume is passionate about people centric leadership, innovation, and the responsible adoption of digital and AI enabled solutions to increase efficiency and scientific value in clinical development.
Appearances:
BioTechX EU Day 2 @ 12:05
Orchestrating the Future of Clinical R&D: From Long-established Expertise to AI‑Driven Expert Agents
For years, digital transformation in clinical R&D has primarily focused on automating existing processes—often reinforcing long‑established functional silos such as data management, statistical programming, analysis, and reporting.
Artificial Intelligence represents a far more structural shift. Rather than simply accelerating current workflows, AI challenges how organizations are designed, governed, and held accountable.
In this joint session, Johnson & Johnson and SAS explore how AI enables a move from siloed execution to an orchestration‑based model, where human experts leverage specialized AI agents across data management, statistical programming, analysis, and reporting.
The discussion highlights how governed, auditable AI platforms make this model operational at scale, while addressing emerging risks and regulatory expectations. A forward‑looking perspective on how health authorities approach AI adoption completes the session.
This session is for leaders looking to understand the fundamental shift in value, from manual production to judgment‑driven decision‑making, coordination, and transparency.
Get involved at BioTechX Europe
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events